AN2 Therapeutics, Inc. (ANTX) financial statements and ratios from SEC XBRL: revenue $2.93M (TTM), net margin -1198.8%, revenue growth -46.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.93M |
| Net Margin | -1198.8% |
| Revenue Growth (YoY) | -46.3% |
| EPS Growth (YoY) | -32.6% |
| Price / Book | 2.88 |
| Price / Sales | 89.23 |
| Altman Z-Score | 7.63 (safe) |
| Sector P/E (Healthcare) | 21.7 |
ANTX overview · ANTX earnings · ANTX KPIs · ANTX investor relations · ANTX ownership · ANTX peers · ANTX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.